

Federal Employee Program.

BACLOFEN ORAL

Fleqsuvy (baclofen) oral suspension, Lyvispah (baclofen) oral granules, Ozobax (baclofen) oral solution

This policy does not apply to any other forms of baclofen not listed above

Pre - PA Allowance

None

Prior-Approval Requirements

Age 12 years of age or older

Diagnosis

Patient must have **ONE** of the following:

- 1. Spasticity related to multiple sclerosis (MS)
- 2. Spinal cord injury or other spinal cord disease

AND ALL of the following:

- a. Patient is unable to swallow or has difficulty swallowing baclofen tablets
- b. Prescriber agrees to monitor for:
 - i. Psychotic disorders, schizophrenia, and confusional states
 - ii. Autonomic dysreflexia
 - iii. Epilepsy

Prior - Approval Limits

Quantity

Drug/Strength	Quantity
Fleqsuvy 5 mg/mL oral suspension	12 x 120mL bottles (1440 mL) per 90 days OR
	5 x 300mL bottles (1500 mL) per 90 days OR
Ozobax 5 mg/5 mL oral solution	16 x 473 mL bottles (7568 mL) per 90 days OR
Ozobax 10 mg/5 mL oral solution	16 x 237 mL bottles (3792 mL) per 90 days OR
	8 x 473 mL bottles (3784 mL) per 90 days OR
Lyvispah 5 mg oral granules	
Lyvispah 10 mg oral granules	80 mg per day
Lyvispah 20 mg oral granules	

Duration 12 months



Federal Employee Program.

BACLOFEN ORAL

Fleqsuvy (baclofen) oral suspension, Lyvispah (baclofen) oral granules, Ozobax (baclofen) oral solution

This policy does not apply to any other forms of baclofen not listed above

Prior - Approval Renewal Requirements

Same as above

Prior - Approval Renewal Limits

Same as above